reason report
valu micro-dystrophin program micro pt
bottom line sarepta one three compani develop micro-
dystrophin gene therapi duchenn muscular dystrophi dmd
competit nr acquir bamboo
op solid clinic hold still
place link sarepta could potenti first-to-mkt
expect report first clinic data micro-dystrophin
candid day june anticip potenti
strong clinic data micro-dystrophin gene therapi
ad probability-weight contribut micro-dystrophin
gene therapi revenu model increas
valuat think logic consid
current valuat reiter op rate
rais pt previous
expect preliminari updat day
express would mark home run outcom midst
updat event expect disproportion amount investor
interest ph i/ii micro-dystrophin data earn call management
establish threshold accept micro-dystrophin express
suggest would repres clear success versu
golodirsen exon dystrophin express level
higher express could confer robust function
clinic benefit pt preclin data particular gene therapi
construct present although note vg/kg
dose sarepta/genethon construct produc express
vg/kg dose solid bioscienc construct produc
express dmd dog link see page think good
potenti upsid home run level set
beyond averag level express western blot
uniform express proper protein local
immunohistochemistri interest sinc may provid
insight eventu clinic benefit potenti abil next-
gener construct improv upon earlier gener one
neuromuscular specialist believ uniform express
lower level better higher degre express
mosaic pattern grant may matter sarepta stock
junctur sinc like trade primarili base averag
level express report strong uptak sinc
approv loosen payor restrict lead us believ
express like view bare minimum clinic
meaning level consequ express push stock
higher recognit higher dose lead express
protect stock downsid amount express
fail impress first dose level vg/kg
net debt total capit
compani inform leerink partner llc research
revenu million ep
pleas refer page import disclosur price chart analyst certif
howev micro-dystrophin program still
uncertainti first fda endors dystrophin surrog
marker efficaci dmd clinic trial link view
micro-dystrophin less clear second function biolog
ramif truncat repeat region dystrophin micro-
dystrophin remain seen particularli dystrophin interact
sever protein dystrophin-associ protein complex/
dapc confer clinic benefit lastli sinc lead caus
mortal dmd pt cardiopulmonari whether increas micro-
skelet muscl prolong life expect improv qualiti
life qol long-term question uncertainti
may address data present day although
sarepta collabor mind design
sale program risk-adjust assum
unperturb pt enrol posit clinic data estim
sarepta micro-dystrophin gene therapi enter market given
sarepta advanc golodirsen casimersen assum
micro-dystrophin program larg address pt address
current exon skipper drug pend clariti academ
commun junctur assum popul pre-
exist neutral antibodi vector use sarepta
program lastli upon fda approv management time
state net annual cost per pt appli figur
luxturna price framework gene therapi equival
mo direct medic cost see medacorp payor consult
take least per pt could justifi said
weight-bas price could render signific
underestim price effect gene therapi think
preliminari price assumpt eu take
factor account pend approval/pr determin
golodirsen and/or casimersen result peak global sale estim
approv eteplirsen sept address approxim
duchenn muscular dystrophi dmd patient suffer mutat dystrophin gene
amen exon estim eteplirsen applic
dmd patient eu sarepta use proprietari phosphorodiamid
morpholino oligom pmo chemistri develop exon skip drug
casimersen oper mechan may
abl amelior progress dmd patient variou disease-caus mutat
consid rariti sever dmd lack optim treatment prevent
progress muscl deterior lead complic respiratori cardiac
function afflict boy expedited/mor lenient path approv may possibl
addit vocal patient-advocaci group new administr
seem favor acceler treatment option rare diseas link could provid
tailwind program develop sarepta current model peak probability-
weight ww revenu addit
revenu deriv follow-on candid
even greater efficaci dystrophin restor superior pmo-bas candid
pend satisfactori progress could gener dystrophin data lastli sarepta
diversifi approach forg collabor partnership nationwid children
hospit summit smmt nr catabasi catb nr investig mechan
could benefit dmd patient either monotherapi synergist sarepta
drug candid importantli first updat micro-dystrophin gene therapi program
 day june could extend sarepta promin dmd ahead competitor
op nr potenti tailwind compani gene therapi program
estim risk-adjust per share fair valu month
current model peak probability-weight eteplirsen/exondi ww revenu
addit revenu deriv follow-on candid
acknowledg sarepta lead posit dmd gene therapi also
includ peak probability-weight micro-dystrophin ww revenu
eteplirsen/exondi micro-
dystrophin rest net cash use wacc discount rate assum
us eu probabl eteplirsen/exondi approv commerci
success longer term assum termin growth rate may warrant
adjust pend fda decis confirmatori studi sinc eteplirsen stand valid
mechan action subsequ exon-skipp assign probabl
success po us/eu respect us/eu
respect po potenti launch us
eu micro-dystrophin po us/eu in-lin op
market entri
risk includ potenti disappoint clinic data regulatori setback commerci
shortfal sinc sarepta eteplirsen approv us acceler approv
proprietari pipelin util chemic formul setback ex-u may rais issu
pipelin valuat although sarepta partnership in-licens candid could
help solidifi compani leadership dmd increas risk potenti cannib
potenti risk futur
litig licens charg
chang
equiti
clinic regulatori mileston
final protocol confirmatori trial submiss
phase essenc enrol complet
ind
updat essenc protocol amend casimersen
roll nda submiss golodirsen
ind
